Recent Updates
Recently added Catalysts

oxaliplatine/ gemcitabine/ Vinorelbine

Phase 2

Non Small Cell Lung Cancer | Small molecule | Oncology |Sanofi|Last Updated: Dec 7, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

oxaliplatine/ gemcitabine/ Vinorelbine · 1 trial · 1 indication

Phase 2 1
NCT00271271Efficacy Study of GEMOX Combination and Vinorelbine in NSCL PatientsNon Small Cell Lung Cancer
COMPLETED40 Analytics
PHASE2COMPLETED
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
Non Small Cell Lung Cancer
NCT0027127140
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective rate of response (ORR) according to the RECIST criterion, as evaluated by a review panel of outside experts.

Secondary Endpoints

Progression free survival (PFS), Overall survival (OS)
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
oxaliplatine / gemcitabine / VinorelbineDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Non-small cell bronchopulmonary cancer established by histological and/or cytological methods; * Advanced or metastatic disease (stage IIIB or IV); * At least one measurable lesion with one dimension (\>= 20 mm by CT scan or \>=10 mm by CT scan) outside of the irradiated area;...

Countries:France
Unlock Eligibility Criteria

Competitive Landscape -Non-Small Cell Lung Cancer 387 trials (matched to "Non Small Cell Lung Cancer")

Top 20 of 83 competitors

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK24PHASE3Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin
AstraZeneca PLCAZN62PHASE3Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin
Revolution Medicines, Inc.RVMD8PHASE3daraxonrasib, docetaxel
Eli Lilly and CompanyLLY18PHASE3Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
AbbVie, Inc.ABBV10PHASE3Telisotuzumab Vedotin, Docetaxel
Bristol-Myers Squibb CompanyBMY18PHASE3Repotrectinib, Crizotinib
BioNTech SE Sponsored ADRBNTX7PHASE3Gotistobart, Docetaxel
Gilead Sciences, Inc.GILD4PHASE3Sacituzumab Govitecan-hziy, Docetaxel
Pfizer Inc.PFE16PHASE3Lorlatinib, Crizotinib
Johnson & JohnsonJNJ17PHASE3Lazertinib, Amivantamab, Pemetrexed, Carboplatin
ArriVent BioPharma, Inc.AVBP9PHASE3Firmonertinib
Amgen Inc.AMGN4PHASE3ABP 234, Pembrolizumab
Novartis AG Sponsored ADRNVS9PHASE3JDQ443, docetaxel
GSK plc Sponsored ADRGSK3PHASE3Dostarlimab, Belrestotug, Pembrolizumab
Summit Therapeutics IncSMMT2PHASE3Ivonescimab, Pembrolizumab
Nuvation Bio, Inc. Class ANUVB4PHASE3Taletrectinib, Crizotinib
Genmab A/S Sponsored ADRGMAB4PHASE3Acasunlimab, Pembrolizumab, Docetaxel
Regeneron Pharmaceuticals, Inc.REGN6PHASE2Cemiplimab, Platinum-based chemotherapy, REGN7075
BeOne Medicines Ltd. Sponsored ADRONC6PHASE3Tislelizumab, Cisplatin, Paclitaxel, Pemetrexed Disodium, Carboplatin
BeyondSpring Inc.BYSI1PHASE3Plinabulin, Docetaxel
Unlock Competitive Intelligence